dpp-4 and glp-1 together DPP4 Inhibitors vs Agonists | June 2021 | Clinical Corner DPP4 Inhibitors vs GLP-1 Agonists
Description
95% CI 0.750.98, p=0.03), Dulaglutide (RR 0.82, 95% CI 0.700.96, p=0.02), Albiglutide (RR 0.93,95% CI 0.791.10, p=0.40), Exenatide (RR 0.93, 95% CI 0.741.18, p=0.55), Lixisenatide (RR 0.83, 95% CI 0.621.12, p=0.22), and Efpeglenatide (RR 0.76, 95% CI 0.461.24, p=0.27)
They're high in protein, low in sugar, and perfect for weight loss and balanced snacking.
Working with George Karavetsos, former director of FDA's Office of Criminal...
Research shows that nearly 90% of people with type 2 diabetes also struggle with their weight, and these medications solve both problems at once
400k posts
